GANX (Gain Therapeutics) GF Score: 32/100 (As of Jul. 01, 2026) — 52% Above Median


GANX Gain Therapeutics Inc GANX
32 GF Score
Price $1.99
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics GF Score?

Gain Therapeutics GANX -1.97% 32 GF Score is 32 as of Jul. 01, 2026, which is 52% above its 10-year median of 21.00. GuruFocus rates GANX with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Gain Therapeutics has the GF Score of 32, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 9/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Gain Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Gain Therapeutics  (NAS:GANX) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Gain Therapeutics GF Score Related Terms

GANX vs HYFT, ELTX, ANVS: GF Score Comparison

For the Biotechnology subindustry, Gain Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gain Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gain Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Gain Therapeutics's GF Score falls into.


GANX
32GF Score
Gain Therapeutics Inc GANX
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 32 mean?
Gain Therapeutics (GANX) has a GF Score of 32 as of Jul. 01, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Gain Therapeutics and its competitors. This is 52% above median its historical median of 21.00. Over the past decade, Gain Therapeutics' GF Score has ranged from 14.00 to 76.00.
Is Gain Therapeutics' GF Score too high?
Gain Therapeutics' current GF Score of 32 is 52% above median its 10-year median of 21.00. Over the past 10 years, this metric has ranged from a low of 14.00 to a high of 76.00. Overall, Gain Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Gain Therapeutics' GF Score compare to HYFT and ELTX?
Gain Therapeutics' GF Score of 32 can be compared against companies in the Biotechnology industry. Historically, Gain Therapeutics' own GF Score has ranged from 14.00 to 76.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Gain Therapeutics and its competitors. Gain Therapeutics's current GF Score is 32, which is 52% above median its own 10-year median of 21.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gain Therapeutics stock overvalued right now?
Gain Therapeutics (GANX) has a current GF Score of 32. The current GF Score is 32, which is 52% above median its 10-year median of 21.00. Gain Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Gain Therapeutics (GANX), the current GF Score is 32 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
32GF Score

Get the complete analysis for GANX

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price